Evonetic is a synthetic biology company that is looking to develop a desktop platform for scalable, high-fidelity and rapid gene synthesis. In partnering with imec, a leading research and
innovation hub active in the fields of nanoelectronics and digital technologies, it is looking to increase production of its proprietary microelectromechanical systems (MEMS)-based silicon chips, enabling the platform to be manufactured at a commercial scale.
The novel silicon chip is a key component of Evonetix’s desktop DNA platform which, once fully developed, will enable the rapidly growing field of synthetic biology.
Evonetix’s technology utilises a silicon chip, made by MEMS processing, that controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion.
Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, enabling accuracy, scale and speed that is several orders of
Commenting Dr Matthew Hayes, Chief Technology Officer at Evonetix, said: “With the support of imec, a world-renowned leader in microchip technology, we will be able to optimise our highly parallel desktop platform for commercial supply.”
